Practice

AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1

September 18th 2024

By Skylar Jeremias

Article

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).

Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys

September 16th 2024

By Skylar Jeremias

Article

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.

Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA

September 14th 2024

By Deana Ferreri, PhD

Article

A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.

Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD

September 7th 2024

By Deana Ferreri, PhD

Article

Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).

Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg

September 3rd 2024

By Cameron Santoro

Article

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

Biosimilar Uptake Lags in US Despite Potential Cost Savings

September 2nd 2024

By Cameron Santoro

Article

Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.

No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors

August 15th 2024

By Skylar Jeremias

Article

An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.

AI and Biosimilars: Bridging Global Health Disparities and Enhancing Treatment Efficiency

August 10th 2024

By Skylar Jeremias

Article

Artificial intelligence (AI) technologies can support global health systems in integrating biosimilars into care models, reducing health care costs, enhancing treatment decision-making strategies, and narrowing the gap between high-income and low- and middle-income countries.

Manitoba Adopts Biosimilar Switching Policy

August 7th 2024

By Skylar Jeremias

Article

Manitoba’s new policy means that all 10 Canadian provinces now have an initiative to boost biosimilar adoption and savings by transitioning patients on reference agents to biosimilar options.

Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US

August 5th 2024

By Skylar Jeremias

Article

The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.